002907.SZ
Chongqing Pharscin Pharmaceutical Co., Ltd. [002907.SZ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
002907.SZ Stock Summary
Top 10 Correlated ETFs
002907.SZ
Top 10 Correlated Stocks
002907.SZ
In the News
002907.SZ Financial details
Company Rating
Neutral
Market Cap
5.65B
Income
32.7M
Revenue
691.54M
Book val./share
-
Cash/share
-
Dividend
0.07
Dividend %
0.45%
Employees
1.42K
Optionable
No
Shortable
Yes
Earnings
29 Apr 2022
P/E
91.6
Forward P/E
-
PEG
-16.57
P/S
8.82
P/B
3.95
P/C
-
P/FCF
386.8
Quick Ratio
3.73
Current Ratio
5.17
Debt / Equity
0
LT Debt / Equity
0
-
-
EPS (TTM)
0.11
EPS next Y
-
EPS next Q
-
EPS this Y
-67.38%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-28.53%
Revenue last 5Y
-3.86%
Revenue Q/Q
13.88%
EPS Q/Q
-
-
-
-
-
SMA20
-11.78%
SMA50
-6.76%
SMA100
-23.28%
Inst Own
-
Inst Trans
-
ROA
4%
ROE
4%
ROC
0.05%
Gross Margin
58%
Oper. Margin
11%
Profit Margin
10%
Payout
43%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9.82-20.5
52W High
-36%
52W Low
+42.22%
RSI
39.52
Rel Volume
0.24
Avg Volume
5.19M
Volume
1.25M
Perf Week
-7.78%
Perf Month
-6.71%
Perf Quarter
-19.75%
Perf Half Y
-27.81%
-
-
-
-
Beta
-0.219
-
-
Volatility
0.44%, 0.81%
Prev Close
0.31%
Price
12.8
Change
-1.39%
002907.SZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.1 | 2.2 | 2.11 | 1.95 | 1.66 | |
| Net income per share | 0.42 | 0.3 | 0.23 | 0.24 | 0.08 | |
| Operating cash flow per share | 0.16 | 0.28 | 0.21 | 0.03 | 0.53 | |
| Free cash flow per share | 0 | 0.17 | 0.07 | -0.12 | 0.3 | |
| Cash per share | 1.2 | 1.33 | 1.27 | 1.2 | 0.86 | |
| Book value per share | 2.68 | 2.95 | 3.16 | 3.99 | 3.87 | |
| Tangible book value per share | 2.48 | 2.77 | 2.91 | 3.71 | 3.49 | |
| Share holders equity per share | 2.68 | 2.95 | 3.16 | 3.99 | 3.87 | |
| Interest debt per share | 0.61 | 0.66 | 0.67 | 0.04 | 0 | |
| Market cap | 6.67B | 5.37B | 7.23B | 8.21B | 6.45B | |
| Enterprise value | 6.6B | 5.14B | 7.05B | 7.7B | 6.01B | |
| P/E ratio | 39.26 | 45.1 | 78.76 | 83.41 | 197.32 | |
| Price to sales ratio | 7.92 | 6.09 | 8.54 | 10.45 | 9.33 | |
| POCF ratio | 101.11 | 47.3 | 87.25 | 629.16 | 29.42 | |
| PFCF ratio | 5.32K | 80.28 | 275.8 | -172.52 | 51 | |
| P/B Ratio | 6.22 | 4.55 | 5.71 | 5.1 | 3.99 | |
| PTB ratio | 6.22 | 4.55 | 5.71 | 5.1 | 3.99 | |
| EV to sales | 7.84 | 5.83 | 8.33 | 9.81 | 8.7 | |
| Enterprise value over EBITDA | 28.83 | 25.75 | 36.98 | 38.44 | 49.37 | |
| EV to operating cash flow | 100.11 | 45.24 | 85.1 | 590.58 | 27.42 | |
| EV to free cash flow | 5.27K | 76.79 | 268.98 | -161.94 | 47.54 | |
| Earnings yield | 0.03 | 0.02 | 0.01 | 0.01 | 0.01 | |
| Free cash flow yield | 0 | 0.01 | 0 | -0.01 | 0.02 | |
| Debt to equity | 0.22 | 0.21 | 0.2 | 0 | 0 | |
| Debt to assets | 0.14 | 0.14 | 0.14 | 0 | 0 | |
| Net debt to EBITDA | -0.29 | -1.17 | -0.94 | -2.51 | -3.59 | |
| Current ratio | 2.88 | 3.48 | 4.32 | 4.53 | 4.74 | |
| Interest coverage | 21.55 | 7.99 | 5.67 | 7.55 | 48.47 | |
| Income quality | 0.39 | 0.95 | 0.9 | 0.13 | 6.71 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0.09 | 0.16 | 0.15 | 0.23 | 0.92 | |
| Sales general and administrative to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Research and developement to revenue | 0.03 | 0.04 | 0.05 | 0.07 | 0.11 | |
| Intangibles to total assets | 0.05 | 0.04 | 0.06 | 0.06 | 0.09 | |
| Capex to operating cash flow | -0.98 | -0.41 | -0.68 | -4.65 | -0.42 | |
| Capex to revenue | -0.08 | -0.05 | -0.07 | -0.08 | -0.13 | |
| Capex to depreciation | -2.73 | -1 | -0.81 | -0.81 | -1.13 | |
| Stock based compensation to revenue | 0.01 | 0 | 0 | 0 | 0 | |
| Graham number | 5.05 | 4.44 | 4.04 | 4.68 | 2.61 | |
| ROIC | 0.13 | 0.08 | 0.06 | 0.06 | 0.02 | |
| Return on tangible assets | 0.11 | 0.07 | 0.05 | 0.06 | 0.02 | |
| Graham Net | 0.46 | 0.57 | 0.64 | 1.34 | 0.94 | |
| Working capital | 568.39M | 633.21M | 687.13M | 745.63M | 705.96M | |
| Tangible asset value | 993.17M | 1.11B | 1.17B | 1.5B | 1.46B | |
| Net current asset value | 304.83M | 349.42M | 388.53M | 700.67M | 661.11M | |
| Invested capital | 0.22 | 0.21 | 0.2 | 0 | 0 | |
| Average receivables | 291.33M | 271.44M | 244.23M | 294.53M | 296.89M | |
| Average payables | 102.19M | 118.07M | 84.07M | 62.07M | 51.64M | |
| Average inventory | 71.38M | 102.48M | 123M | 121.1M | 133.22M | |
| Days sales outstanding | 132.16 | 98.43 | 108.04 | 157.4 | 134.69 | |
| Days payables outstanding | 171.27 | 73.31 | 69.46 | 54.92 | 64.75 | |
| Days of inventory on hand | 102.69 | 94.43 | 116.31 | 131.18 | 177.81 | |
| Receivables turnover | 2.76 | 3.71 | 3.38 | 2.32 | 2.71 | |
| Payables turnover | 2.13 | 4.98 | 5.26 | 6.65 | 5.64 | |
| Inventory turnover | 3.55 | 3.87 | 3.14 | 2.78 | 2.05 | |
| ROE | 0.16 | 0.1 | 0.07 | 0.06 | 0.02 | |
| Capex per share | -0.16 | -0.12 | -0.14 | -0.15 | -0.22 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.55 | 0.45 | 0.41 | 0.37 | 0 | |
| Net income per share | 0.06 | 0.07 | 0.03 | 0.01 | 0 | |
| Operating cash flow per share | 0.06 | 0.07 | 0.13 | 0.06 | 0 | |
| Free cash flow per share | -0.02 | 0.04 | -0.02 | 0.04 | 0 | |
| Cash per share | 1.18 | 1.27 | 1.17 | 0.91 | 0 | |
| Book value per share | 3.94 | 3.92 | 3.9 | 3.91 | 0 | |
| Tangible book value per share | 3.65 | 3.57 | 3.54 | 3.53 | 0 | |
| Share holders equity per share | 3.94 | 3.92 | 3.9 | 3.91 | 0 | |
| Interest debt per share | 0 | 0.17 | 0.17 | 0 | 0 | |
| Market cap | 8.33B | 7.42B | 6.36B | 7.31B | 0 | |
| Enterprise value | 7.83B | 6.95B | 5.92B | 6.85B | -437.28M | |
| P/E ratio | 81.49 | 61.67 | 141.1 | 535.32 | 0 | |
| Price to sales ratio | 37.27 | 39.59 | 36.76 | 47.21 | 0 | |
| POCF ratio | 325.95 | 246.67 | 117.42 | 272.88 | 0 | |
| PFCF ratio | -1.35K | 434.75 | -671.9 | 474.25 | 0 | |
| P/B Ratio | 5.17 | 4.53 | 3.91 | 4.48 | 0 | |
| PTB ratio | 5.17 | 4.53 | 3.91 | 4.48 | 0 | |
| EV to sales | 35.02 | 37.05 | 34.22 | 44.28 | -2.48 | |
| Enterprise value over EBITDA | 289.54 | 194.15 | 551.26 | 1.35K | 36.86 | |
| EV to operating cash flow | 306.26 | 230.82 | 109.32 | 255.95 | -11.2 | |
| EV to free cash flow | -1.27K | 406.82 | -625.58 | 444.84 | -12.78 | |
| Earnings yield | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0 | 0.04 | 0.04 | 0 | 0 | |
| Debt to assets | 0 | 0.04 | 0.04 | 0 | 0 | |
| Net debt to EBITDA | -18.62 | -13.33 | -40.82 | -89.28 | 36.86 | |
| Current ratio | 4.53 | 3.96 | 3.78 | 5.17 | 4.74 | |
| Interest coverage | 700.54 | 210.86 | 24.34 | 16.3 | -206.45 | |
| Income quality | 1 | 1 | 4.81 | 7.85 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0.78 | 0 | 2.64 | 0.1 | 0 | |
| Sales general and administrative to revenue | -0.11 | 0.06 | -0.04 | 0.21 | -0.15 | |
| Research and developement to revenue | 0.09 | 0.08 | 0.09 | 0.13 | 0.16 | |
| Intangibles to total assets | 0.06 | 0.07 | 0.08 | 0.09 | 0.09 | |
| Capex to operating cash flow | -1.24 | -0.43 | -1.17 | -0.42 | -0.12 | |
| Capex to revenue | -0.14 | -0.07 | -0.37 | -0.07 | -0.03 | |
| Capex to depreciation | -1.75 | -0.67 | -3.29 | 0.29 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 2.35 | 2.52 | 1.54 | 0.85 | 0 | |
| ROIC | 0.02 | 0.02 | 0.01 | 0 | -0.01 | |
| Return on tangible assets | 0.01 | 0.02 | 0.01 | 0 | -0.01 | |
| Graham Net | 1.32 | 1.3 | 1.14 | 1.04 | 0 | |
| Working capital | 745.63M | 758.97M | 695.12M | 703.99M | 705.96M | |
| Tangible asset value | 1.5B | 1.49B | 1.48B | 1.47B | 1.46B | |
| Net current asset value | 700.67M | 715.59M | 650.38M | 657.92M | 661.11M | |
| Invested capital | 0 | 0.04 | 0.04 | 0 | 0 | |
| Average receivables | 316.4M | 327.34M | 295.21M | 263.23M | 253.66M | |
| Average payables | 61.39M | 53.76M | 56.11M | 50.61M | 51.85M | |
| Average inventory | 118.66M | 132.57M | 151.73M | 158.19M | 157.49M | |
| Days sales outstanding | 136.35 | 151.69 | 142.78 | 146.59 | 130.28 | |
| Days payables outstanding | 49.04 | 71.91 | 59.33 | 63.95 | 56.05 | |
| Days of inventory on hand | 117.14 | 181.81 | 172.2 | 215.48 | 153.91 | |
| Receivables turnover | 0.66 | 0.59 | 0.63 | 0.61 | 0.69 | |
| Payables turnover | 1.84 | 1.25 | 1.52 | 1.41 | 1.61 | |
| Inventory turnover | 0.77 | 0.5 | 0.52 | 0.42 | 0.58 | |
| ROE | 0.02 | 0.02 | 0.01 | 0 | -0.01 | |
| Capex per share | -0.08 | -0.03 | -0.15 | -0.03 | 0 |
002907.SZ Frequently Asked Questions
What is Chongqing Pharscin Pharmaceutical Co., Ltd. stock symbol ?
Chongqing Pharscin Pharmaceutical Co., Ltd. is a CN stock and trading under the symbol 002907.SZ
What is Chongqing Pharscin Pharmaceutical Co., Ltd. stock quote today ?
Chongqing Pharscin Pharmaceutical Co., Ltd. stock price is $12.8 today.
Is Chongqing Pharscin Pharmaceutical Co., Ltd. stock public?
Yes, Chongqing Pharscin Pharmaceutical Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 5.19M
- Market Capitalization 5.65B
- Employee 1.42K
- CEO Ms. Xiaoying Liu
- Headquarters Chongqing,CN
- IPO Date 2017-10-20
-
Website
https://www.pharscin.com 
Chongqing Pharscin Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of drugs in China. The company offers tablets, powders, granules, hard capsules, soft capsules, powder injections, freeze-dried powder injections, small volume injections, and API synthesis. It provides its products in the areas of CNS, digestion, otolaryngology, oncology, cardiovascular, and cerebrovascular related diseases. Chongqing Pharscin Pharmaceutical Co., Ltd. was founded in 1996 and is headquartered in Chongqing, China.
